These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 20371539)

  • 1. Does stress ulcer prophylaxis explain the association between clostridium difficile-associated disease and mechanical ventilation?
    Porath AD
    Chest; 2010 Apr; 137(4):1001; author reply 1001-2. PubMed ID: 20371539
    [No Abstract]   [Full Text] [Related]  

  • 2. Does confounding explain the association between PPIs and Clostridium difficile-related diarrhea?
    Freedberg DE; Abrams JA
    Am J Gastroenterol; 2013 Feb; 108(2):278-9. PubMed ID: 23381076
    [No Abstract]   [Full Text] [Related]  

  • 3. Proton pump inhibitor use may be associated with an increased risk of Clostridium difficile infection.
    Stevens V; van Wijngaarden E
    Evid Based Med; 2013 Oct; 18(5):193-4. PubMed ID: 23220471
    [No Abstract]   [Full Text] [Related]  

  • 4. Risk of Clostridium difficile infection with acid-suppressive therapy; pitfalls in accurate estimation.
    Chandra S; Agarwal D; Surana A
    Am J Gastroenterol; 2013 Feb; 108(2):277-8. PubMed ID: 23381074
    [No Abstract]   [Full Text] [Related]  

  • 5. Clostridium difficile infection: managing the risks.
    DeDea L
    JAAPA; 2012 May; 25(5):16. PubMed ID: 22712142
    [No Abstract]   [Full Text] [Related]  

  • 6. Response to Chandra et al., and Freedberg and Abrams.
    Loke YK; Kwok CS
    Am J Gastroenterol; 2013 Feb; 108(2):279-80. PubMed ID: 23381077
    [No Abstract]   [Full Text] [Related]  

  • 7. Gastric acid-suppressive agents and risk of Clostridium difficile-associated disease.
    Leffler D; Cloud JW; Kelly CP
    JAMA; 2006 Jun; 295(22):2599-600; author reply 2600-1. PubMed ID: 16772617
    [No Abstract]   [Full Text] [Related]  

  • 8. Proton pump inhibitors and histamine-2 receptor antagonists in the intensive care setting: focus on therapeutic and adverse events.
    MacLaren R; Kassel LE; Kiser TH; Fish DN
    Expert Opin Drug Saf; 2015 Feb; 14(2):269-80. PubMed ID: 25423448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for Clostridium difficile-associated diarrhea and the effectiveness of prophylactic probiotic therapy.
    Mizui T; Teramachi H; Tachi T; Tamura K; Shiga H; Komada N; Umeda M; Koda A; Aoyama S; Goto C; Tsuchiya T
    Pharmazie; 2013 Aug; 68(8):706-10. PubMed ID: 24020129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How much do PPIs contribute to C. difficile infections?
    Leontiadis GI; Miller MA; Howden CW
    Am J Gastroenterol; 2012 Jul; 107(7):1020-1. PubMed ID: 22764024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opinions and practice of stress ulcer prophylaxis in Australian and New Zealand intensive care units.
    Eastwood GM; Litton E; Bellomo R; Bailey MJ; Festa M; Beasley RW; Young PJ
    Crit Care Resusc; 2014 Sep; 16(3):170-4. PubMed ID: 25161018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stress ulcer prophylaxis in the intensive care unit: an international survey of 97 units in 11 countries.
    Krag M; Perner A; Wetterslev J; Wise MP; Borthwick M; Bendel S; McArthur C; Cook D; Nielsen N; Pelosi P; Keus F; Guttormsen AB; Moller AD; Møller MH;
    Acta Anaesthesiol Scand; 2015 May; 59(5):576-85. PubMed ID: 25880349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stress ulcer prophylaxis: friend or foe?
    Macdonald JJ; Roberts JC; Washington S
    Br J Hosp Med (Lond); 2012 Apr; 73(4):238. PubMed ID: 22585209
    [No Abstract]   [Full Text] [Related]  

  • 14. Proton pump inhibitors and the risk for Clostridium difficile infection.
    Famularo G; Gasbarrone L; De Simone C
    JAMA; 2009 Jul; 302(1):31-2; author reply 32. PubMed ID: 19567433
    [No Abstract]   [Full Text] [Related]  

  • 15. Association between gastric acid suppressants and Clostridium difficile colitis and community-acquired pneumonia: analysis using pharmacovigilance tools.
    Hauben M; Horn S; Reich L; Younus M
    Int J Infect Dis; 2007 Sep; 11(5):417-22. PubMed ID: 17336566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What's new with stress ulcer prophylaxis in the ICU?
    Marker S; Krag M; Møller MH
    Intensive Care Med; 2017 Aug; 43(8):1132-1134. PubMed ID: 28238056
    [No Abstract]   [Full Text] [Related]  

  • 17. Association of Gastric Acid Suppression With Recurrent Clostridium difficile Infection: A Systematic Review and Meta-analysis.
    Tariq R; Singh S; Gupta A; Pardi DS; Khanna S
    JAMA Intern Med; 2017 Jun; 177(6):784-791. PubMed ID: 28346595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proton pump inhibitors as a risk factor for paediatric Clostridium difficile infection.
    Turco R; Martinelli M; Miele E; Roscetto E; Del Pezzo M; Greco L; Staiano A
    Aliment Pharmacol Ther; 2010 Apr; 31(7):754-9. PubMed ID: 20047577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cluster randomised, crossover, registry-embedded clinical trial of proton pump inhibitors versus histamine-2 receptor blockers for ulcer prophylaxis therapy in the intensive care unit (PEPTIC study): study protocol.
    Young PJ; Bagshaw SM; Forbes A; Nichol A; Wright SE; Bellomo R; Bailey MJ; Beasley RW; Eastwood GM; Festa M; Gattas D; van Haren F; Litton E; Mouncey PR; Navarra L; Pilcher D; Mackle DM; McArthur CJ; McGuinness SP; Saxena MK; Webb S; Rowan KM;
    Crit Care Resusc; 2018 Sep; 20(3):182-189. PubMed ID: 30153780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histamine-2 receptor antagonists vs proton pump inhibitors on gastrointestinal tract hemorrhage and infectious complications in the intensive care unit.
    MacLaren R; Reynolds PM; Allen RR
    JAMA Intern Med; 2014 Apr; 174(4):564-74. PubMed ID: 24535015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.